Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIB in vivo CAR-T Lentiviral Injection in Advanced Malignant Tumors
NCT07657585Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CIB in vivo CAR-T Lentiviral Injection in advanced malignant solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
CIB in vivo CAR-T Lentiviral Injection
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07657585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657585.